PCI in oversubscribed rights issue following promising clinical oncology data
This article was originally published in Scrip
Executive Summary
PCI Biotech, a Norwegian company which reported promising results from a clinical trial in cancer earlier this year, has raised NOK90 million (£9.5 million) through a new rights issue which was oversubscribed by around 50%.